British Columbia Centre on Substance Use, British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada; Department of Family and Community Medicine, University of Toronto, 500 University Ave, Toronto, ON, M5G 1V7, Canada.
British Columbia Centre on Substance Use, British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada; School of Public Policy, Simon Fraser University, Harbour Centre, 515 West Hastings Street, Vancouver, BC, V6B 5K3, Canada.
Drug Alcohol Depend. 2018 Dec 1;193:42-47. doi: 10.1016/j.drugalcdep.2018.09.003. Epub 2018 Oct 6.
Inability to access opioid agonist therapy (OAT) in correctional settings has previously been reported in Vancouver, Canada, and is associated with harms among people with opioid use disorder (OUD), including overdose death. We investigated the prevalence and correlates of OAT utilization within correctional settings among incarcerated persons with OUD in Vancouver.
Data were derived from three prospective cohorts of people who use drugs in Vancouver between 2005 and 2016. Using multivariable generalized estimating equations, we examined factors associated with OAT utilization among participants with OUD reporting incarceration in the past six months.
Among 597 eligible participants, 207 (34.7%) contributed 325 reports of having utilized OAT while incarcerated. Of those, 295 (90.8%) were continuations and 30 (9.2%) were new initiations of OAT while incarcerated. For those currently on OAT (at the time of interview), in multivariable analyses, non-fatal overdose (adjusted odds ratio [AOR] = 0.49, 95% confidence interval [CI]: 0.29-0.82) and daily prescription opioid use (AOR = 0.42, 95% CI: 0.20-0.85) remained independently and negatively associated with having utilized OAT while incarcerated. For those not currently on OAT, none of the variables considered had significant associations with utilization of OAT while incarcerated.
Utilization of OAT in correctional settings was low in our sample. Utilization of OAT was significantly and negatively associated with overdose and ongoing prescription opioid misuse if OAT was continued upon release from correctional settings. Findings underscore the urgent need for improved utilization of OAT in correctional settings, and linkage to community care to prevent harms such as overdose.
在加拿大温哥华,先前曾有报告称,在惩教场所无法获得阿片类激动剂治疗(OAT),这与包括过量死亡在内的阿片类药物使用障碍(OUD)患者的伤害有关。我们调查了温哥华有 OUD 的被监禁者在惩教场所中接受 OAT 的情况及其流行率和相关因素。
数据来自 2005 年至 2016 年期间在温哥华使用毒品的三个前瞻性队列。使用多变量广义估计方程,我们检查了过去六个月内报告监禁的 OUD 参与者中与 OAT 利用相关的因素。
在 597 名合格参与者中,有 207 名(34.7%)提供了 325 份关于在监禁期间利用 OAT 的报告。其中,有 295 人(90.8%)是在监禁期间继续接受 OAT,有 30 人(9.2%)是新开始接受 OAT。对于那些目前正在接受 OAT(在接受采访时)的人,在多变量分析中,非致命性过量(调整后的优势比 [AOR] = 0.49,95%置信区间 [CI]:0.29-0.82)和每日处方阿片类药物使用(AOR = 0.42,95%CI:0.20-0.85)与在监禁期间利用 OAT 独立且呈负相关。对于那些目前未接受 OAT 的人,所考虑的变量中没有一个与在监禁期间利用 OAT 有显著关联。
我们的样本中,在惩教场所中使用 OAT 的情况很低。如果在从惩教机构释放后继续使用 OAT,OAT 的使用与过量和持续使用处方阿片类药物滥用显著负相关。研究结果强调了迫切需要改善在惩教场所中使用 OAT,并与社区护理联系起来,以预防过量等伤害。